Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Breast 3Thoracic 2Gynecologic 2Head & Neck 1Genitourinary 1

Conditions

Stomach Neoplasms 2Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 37Paclitaxel 18Cisplatin 18Carboplatin 14Nivolumab 13Hyperthermic Intraperitoneal Chemotherapy 13Docetaxel 11Cyclophosphamide 11Oxaliplatin 9Irinotecan 9Fluorouracil 9atezolizumab 8Trastuzumab 8Leucovorin 8Bevacizumab 8fludarabine 7Magnetic Resonance Spectroscopy 7Specimen Handling 6Ipilimumab 6Gemcitabine 6Mitomycin 5Cytoreduction Surgical Procedures 5Capecitabine 5durvalumab 4cemiplimab 4aldesleukin 4Taxes 4Psychiatric Rehabilitation 4Platinum 4Drug Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × zanidatamab × Gynecologic × Clear all
NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Jazz Pharmaceuticals

Phase 1 Completed
279 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡